Join
Live feed
·
PRReleasevia Quantisnow
Eledon Pharmaceuticals Inc. logo

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
ELDN· Eledon Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ELDN (Eledon Pharmaceuticals Inc.) and more on Quantisnow.